genotype phenotype relationship in a cohort of 131 chinese patients with myotonic dystrophy type 1

Original title: “Genotype-phenotype relationship in a cohort of 131 Chinese patients with myotonic dystrophy type 1.”

Analysts homed in on Duchenne muscular dystrophy and myotonic dystrophy type 1 assets during first quarter earnings as major players like REGENXBIO and Novartis as well as Dyne, Wave, Solid and Sarepta near the regulatory finish line.

Original title: “REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies”

evaluating the performance of chatgpt in responding to myotonic dystrophy type 1 patient inquiries a specialist physician based study

Original title: “Evaluating the performance of ChatGPT in responding to myotonic dystrophy type 1 patient inquiries: a specialist physician-based study.”

PepGen’s lead candidate for myotonic dystrophy type 1 barely beat the placebo in a Phase 2 trial in terms of fixing incorrect gene splicing, but the biotech attributed the poor result to an outlier.

Original title: “PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease”

delpacibart etedesiran improves the molecular pathology of myotonic dystrophy type 1 in the phase 1 2 marina study

Original title: “Delpacibart Etedesiran Improves the Molecular Pathology of Myotonic Dystrophy Type 1 in the Phase 1/2 MARINA® Study.”

antibody oligonucleotide conjugate for myotonic dystrophy type 1

Original title: “An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.”

minute by minute gait variations during the 6 minute walk test in subjects with myotonic dystrophy type 1

Original title: “Minute-by minute gait variations during the 6-Minute walk test in subjects with myotonic dystrophy type 1.”